Hyperkalemia Management

Diagnosis and Classification

• Hyperkalemia can be classified into three severity categories: mild (5.5-6.4 mmol/L), moderate (6.5-8.0 mmol/L), and severe (>8.0 mmol/L), with a strength of evidence level of high, as defined by the European Heart Society 1
• The relationship between potassium levels and mortality follows a U-shaped curve, with increased mortality risk at levels <3.5 mmol/L and >5.0 mmol/L, and lowest mortality risk at levels between 3.5-4.5 mmol/L, as confirmed by multiple studies across various patient populations, including those with heart failure, hypertension, and myocardial infarction, with a high strength of evidence, as supported by the American College of Cardiology and the European Society of Cardiology 2
• The following table summarizes the potassium levels and corresponding mortality risk:

Risk Factors and Prevention

• Patients with significantly impaired renal function, such as an eGFR of 26 ml/min/1.73m², are at increased risk of spironolactone-induced hyperkalemia, according to the European Society of Cardiology 3
• The combination of spironolactone with other RAAS inhibitors, like empagliflozin, further increases the risk of hyperkalemia, as stated by the European Society of Cardiology 3
• Medication interactions, especially with antihypertensives, should be considered as a potential cause of hyperkalemia, according to the American Geriatrics Society 4
• Consider using SGLT2 inhibitors, which can reduce hyperkalemia risk (hazard ratio 0.84; 95% CI 0.76-0.93) and provide additional cardiovascular benefits, according to the American Journal of Kidney Diseases 5
• Switching to sacubitril/valsartan may be considered, as it has a lower hyperkalemia risk compared to ACE inhibitors (hazard ratio 1.37; 95% CI 1.06-1.76 for enalapril vs. sacubitril/valsartan), as recommended by the American Journal of Kidney Diseases 5

Treatment and Management

• For a potassium level of 5.6 mEq/L, which represents moderate hyperkalemia, implement dietary potassium restriction, review and adjust medications that may contribute to hyperkalemia, and consider oral potassium binders if necessary, according to the European Society of Cardiology guidelines 3
• The European Society of Cardiology recommends discontinuing spironolactone in patients with significant hyperkalemia and renal dysfunction to minimize cardiac risk 6
• After potassium levels normalize, considering a lower dose of spironolactone (e.g., 25 mg on alternate days) with close monitoring, or optimizing other guideline-directed medical therapy medications, is a potential alternative strategy, according to the European Society of Cardiology 6
• Review medications that may contribute to hyperkalemia, such as ACE inhibitors, ARBs, and potassium-sparing diuretics, to minimize risk, as recommended by the American Geriatrics Society 4
• Potassium binders, such as patiromer, can be considered for patients with current or history of hyperkalemia, with patiromer significantly reducing hyperkalemia rates compared to placebo (hazard ratio 0.63; 95% CI 0.45-0.87), according to the European Heart Journal 5
• Thiazide diuretics may help lower potassium levels but require careful monitoring, according to the American Geriatrics Society 4

Monitoring and Follow-up

• Recheck potassium and renal function within 2-3 days of initiating treatment, and repeat at 7 days after initiation, as recommended by the American Heart Association 7
• Monthly monitoring for the first 3 months is recommended, and every 3 months thereafter if stable, according to the American Heart Association 7
• Serial measurements of potassium and renal function are essential after identifying hyperkalemia, with recheck potassium and renal function within 2-3 days and continue monitoring monthly for at least 3 months, as recommended by the American College of Cardiology and the European Society of Cardiology, with a high strength of evidence 2
• Verify true hyperkalemia with repeat testing to rule out pseudohyperkalemia (hemolysis, poor phlebotomy technique, fist clenching), as recommended by the American Heart Association, with a moderate strength of evidence 8

Dietary Recommendations

• Restrict dietary potassium intake to less than 2,000-3,000 mg (50-75 mmol) daily, and advise patients to avoid high-potassium foods such as bananas, oranges, potatoes, tomato products, legumes, lentils, yogurt, and chocolate, with a moderate strength of evidence, as recommended by the American College of Cardiology 9
• Patients should avoid salt substitutes containing potassium, as recommended by the American Heart Association, with a moderate strength of evidence 10, 9
• If potassium remains elevated (>5.0 mEq/L), advise temporary reduction in high-potassium foods (including avocados) and check for other potential causes (medications, renal function), as recommended by the Mayo Clinic, with a moderate strength of evidence 8

Common Pitfalls and Considerations

• Ignoring mild hyperkalemia can lead to progression and should be addressed proactively, according to the European Society of Cardiology, with a moderate to high strength of evidence 5
• Failing to consider pseudohyperkalemia can lead to incorrect diagnosis and treatment, as suggested by the American College of Cardiology, with a moderate strength of evidence 5
• Inadequate monitoring can lead to poor outcomes, and focusing only on potassium levels can compromise beneficial therapies, according to the European Heart Journal, with a moderate to high strength of evidence 5
• Discontinuing guideline-directed medical therapy (GDMT) is associated with poorer clinical outcomes, as reported by the American Journal of Kidney Diseases 5
• Discontinuing GDMT prematurely is associated with poorer clinical outcomes, as per the American Heart Association, with a high strength of evidence 5
• Common pitfalls in hyperkalemia management include ignoring mild or moderate hyperkalemia, discontinuing beneficial medications rather than adjusting doses, failing to consider other factors that influence complication risk, inadequate monitoring after initiating treatment, and failing to recognize pseudo-hyperkalemia (hemolysis during blood draw), as noted by the European Society of Cardiology and the European Journal of Heart Failure, with a moderate to high strength of evidence 3, 2, 8